Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell"

Key Points

• Wall Street Zen downgraded Keros Therapeutics to “strong sell,” although other analysts remain more positive. MarketBeat’s consensus rating is “hold,” with an average price target of $20.50.
• KROS shares opened at $11.32, up 1.9%, but the company reported a quarterly loss of $1.45 per share, missing estimates of a $1.34 loss. Analysts expect a full-year loss of approximately $5.27 per share.
• An insider sold 3,568 shares for about $36,715 to cover tax withholding obligations, while institutional investors own 71.56% of the stock.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued reports about the stock. Leerink Partners decreased their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an "outperform" rating for the company in a research report on Tuesday, August 4th. Zacks Research raised shares of Keros Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 27th. Wells Fargo & Company cut their price target on Keros Therapeutics from $20.00 to $18.00 and set an "overweight" rating for the company in a research note on Tuesday, August 4th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Keros Therapeutics in a report on Tuesday, August 4th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Keros Therapeutics has a consensus rating of "Hold" and an average price target of $20.50.

Keros Therapeutics Trading Up 1.9%

NASDAQ KROS opened at $11.32 on Friday. The company has a fifty day simple moving average of $10.81 and a 200 day simple moving average of $11.40. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55. The company has a market cap of $224.48 million, a P/E ratio of -3.06 and a beta of 1.01.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Sell-side analysts predict that Keros Therapeutics will post -5.27 EPS for the current year.

Insider Activity

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares in the company, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 5,893 shares of company stock valued at $60,507. Corporate insiders own 12.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Keros Therapeutics by 72.6% in the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company's stock valued at $29,000 after buying an additional 1,148 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company's stock worth $33,000 after buying an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company's stock worth $42,000 after buying an additional 1,888 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Keros Therapeutics in the second quarter valued at approximately $90,000. Finally, PDT Partners LLC bought a new position in shares of Keros Therapeutics in the second quarter valued at approximately $122,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc NASDAQ: KROS is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company's research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company's lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source